| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0035 | 0.9 |